Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) EBIT : $5.26 Mil (TTM As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings EBIT?

Parnell Pharmaceuticals Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2018 was $5.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2018 was $5.26 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Parnell Pharmaceuticals Holdings's annualized ROC % for the quarter that ended in Dec. 2018 was 5.18%. Parnell Pharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2018 was 66.99%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Parnell Pharmaceuticals Holdings EBIT Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings EBIT Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

EBIT

Get a 7-Day Free Trial

-6.64

-9.02

-13.12

-10.61

5.26

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
EBIT	Get a 7-Day Free Trial			-6.64	-9.02	-13.12	-10.61	5.26

Competitive Comparison of Parnell Pharmaceuticals Holdings's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's EV-to-EBIT falls into.

Parnell Pharmaceuticals Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2018 was $5.26 Mil.

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Parnell Pharmaceuticals Holdings's annualized ROC % for the quarter that ended in Dec. 2018 is calculated as:

	ROC % (Q: Dec. 2018 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2017 )	+	Invested Capital (Q: Dec. 2018 ))	/ count )
=	2.451 * ( 1 - 61.16% )	/	( (19.192	+	17.56)	/ 2 )
=	0.9519684	/	18.376
=	5.18 %

where

	Invested Capital		(Q: Dec. 2017 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	23.092	-	4.94	-	( 1.819	-	max(0, 6.68	-	5.64	+	1.819	))
=	19.192

	Invested Capital		(Q: Dec. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	24.003	-	4.282	-	( 3.155	-	max(0, 4.849	-	7.01	+	3.155	))
=	17.56

Note: The Operating Income data used here is one times the annual (Dec. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

Parnell Pharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2018 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2018 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2017		Q: Dec. 2018
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	5.256	/	( ( (8.099 + max(-4.073, 0))	+	(7.594 + max(-1.031, 0)) )	/	2 )
=	5.256	/	( ( 8.099	+	7.594 )	/	2 )
=	5.256	/	7.8465
=	66.99 %

where Working Capital is:

	Working Capital		(Q: Dec. 2017 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.731	+	1.633	+	0.235)	-	(4.94	+	1.291	+	0.441)
=	-4.073

	Working Capital		(Q: Dec. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.203	+	2.29	+	0.318)	-	(4.282	+	0	+	0.56)
=	-1.031

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Parnell Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2018 )
	=	5.256	/	0.000
	=	%

Parnell Pharmaceuticals Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.